Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
62 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Cell Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Cell Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Cell Therapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Cell Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Cell Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Cell Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Cell Therapeutics, Inc.'s pipeline products Reasons to buy - Evaluate Cell Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Cell Therapeutics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Cell Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Cell Therapeutics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cell Therapeutics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Cell Therapeutics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Cell Therapeutics, Inc. Snapshot 5 Cell Therapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 Cell Therapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Cell Therapeutics, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Cell Therapeutics, Inc. - Pipeline Products Glance 13 Cell Therapeutics, Inc. - Late Stage Pipeline Products 13 Filing rejected/Withdrawn Products/Combination Treatment Modalities 13 Phase III Products/Combination Treatment Modalities 14 Cell Therapeutics, Inc. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Cell Therapeutics, Inc. - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Cell Therapeutics, Inc. - Drug Profiles 18 paclitaxel poliglumex 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 pixantrone dimaleate 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 pacritinib 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 brostallicin 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 lisofylline 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 CT-1578 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 CT-47463 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Cell Therapeutics, Inc. - Pipeline Analysis 34 Cell Therapeutics, Inc. - Pipeline Products by Target 34 Cell Therapeutics, Inc. - Pipeline Products by Route of Administration 36 Cell Therapeutics, Inc. - Pipeline Products by Molecule Type 37 Cell Therapeutics, Inc. - Pipeline Products by Mechanism of Action 38 Cell Therapeutics, Inc. - Recent Pipeline Updates 40 Cell Therapeutics, Inc. - Dormant Projects 52 Cell Therapeutics, Inc. - Discontinued Pipeline Products 54 Discontinued Pipeline Product Profiles 54 CT-2584 54 nortopixantrone 54 topixantrone 54 Cell Therapeutics, Inc. - Company Statement 55 Cell Therapeutics, Inc. - Locations And Subsidiaries 60 Head Office 60 Other Locations & Subsidiaries 60 Appendix 61 Methodology 61 Coverage 61 Secondary Research 61 Primary Research 61 Expert Panel Validation 61 Contact Us 62 Disclaimer 62
List of Tables Cell Therapeutics, Inc., Key Information 5 Cell Therapeutics, Inc., Key Facts 5 Cell Therapeutics, Inc. - Pipeline by Indication, 2014 7 Cell Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9 Cell Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10 Cell Therapeutics, Inc. - Partnered Products in Pipeline, 2014 11 Cell Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12 Cell Therapeutics, Inc. - Filing rejected/Withdrawn, 2014 13 Cell Therapeutics, Inc. - Phase III, 2014 14 Cell Therapeutics, Inc. - Phase II, 2014 15 Cell Therapeutics, Inc. - Phase I, 2014 16 Cell Therapeutics, Inc. - Preclinical, 2014 17 Cell Therapeutics, Inc. - Pipeline by Target, 2014 35 Cell Therapeutics, Inc. - Pipeline by Route of Administration, 2014 36 Cell Therapeutics, Inc. - Pipeline by Molecule Type, 2014 37 Cell Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 39 Cell Therapeutics, Inc. - Recent Pipeline Updates, 2014 40 Cell Therapeutics, Inc. - Dormant Developmental Projects,2014 52 Cell Therapeutics, Inc. - Discontinued Pipeline Products, 2014 54 Cell Therapeutics, Inc., Subsidiaries 60
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.